2023

1. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

   Japanese Journal of Ophthalmology, Vol. 67, Núm. 3, pp. 264-279